Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Intervalo de ano de publicação
1.
Mol Biol Cell ; 18(3): 743-54, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17182845

RESUMO

Transferrin receptor 2 (TfR2) is a homologue of transferrin receptor 1 (TfR1), the protein that delivers iron to cells through receptor-mediated endocytosis of diferric transferrin (Fe(2)Tf). TfR2 also binds Fe(2)Tf, but it seems to function primarily in the regulation of systemic iron homeostasis. In contrast to TfR1, the trafficking of TfR2 within the cell has not been extensively characterized. Previously, we showed that Fe(2)Tf increases TfR2 stability, suggesting that trafficking of TfR2 may be regulated by interaction with its ligand. In the present study, therefore, we sought to identify the mode of TfR2 degradation, to characterize TfR2 trafficking, and to determine how Fe(2)Tf stabilizes TfR2. Stabilization of TfR2 by bafilomycin implies that TfR2 traffics to the lysosome for degradation. Confocal microscopy reveals that treatment of cells with Fe(2)Tf increases the fraction of TfR2 localizing to recycling endosomes and decreases the fraction of TfR2 localizing to late endosomes. Mutational analysis of TfR2 shows that the mutation G679A, which blocks TfR2 binding to Fe(2)Tf, increases the rate of receptor turnover and prevents stabilization by Fe(2)Tf, indicating a direct role of Fe(2)Tf in TfR2 stabilization. The mutation Y23A in the cytoplasmic domain of TfR2 inhibits its internalization and degradation, implicating YQRV as an endocytic motif.


Assuntos
Endocitose , Receptores da Transferrina/metabolismo , Sequência de Aminoácidos , Linhagem Celular Tumoral , Endocitose/efeitos dos fármacos , Humanos , Ligantes , Lisossomos/efeitos dos fármacos , Macrolídeos/farmacologia , Dados de Sequência Molecular , Proteínas Mutantes/metabolismo , Mutação/genética , Ligação Proteica/efeitos dos fármacos , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Estrutura Terciária de Proteína/efeitos dos fármacos , Transporte Proteico/efeitos dos fármacos , Receptores da Transferrina/química , Receptores da Transferrina/genética , Frações Subcelulares/efeitos dos fármacos , Termodinâmica , Transfecção , Transferrina/metabolismo , Tirosina/metabolismo
2.
Neurobiol Dis ; 32(3): 442-53, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18804535

RESUMO

Preconditioning brain with a sub-lethal stressor can temporarily generate a damage-refractory state. Microarray analyses have defined the changes in hippocampal gene expression that follow brief preconditioning seizures, but not the transcriptome after a prolonged and otherwise injurious seizure in previously preconditioned brain. Presently, microarray analysis was performed 24 h after status epilepticus in mice that had received previously either seizure preconditioning (tolerance) or sham-preconditioning (injury). Transcriptional changes in the hippocampal CA3 subfield of >or=2 fold were detected for 1357 genes in the tolerance group compared to a non-seizure control group, with 54% up-regulated. Of these regulated genes, 792 were also regulated in the injury group. Among the remaining 565 genes regulated only in tolerance, 73% were down-regulated. Analysis of the genes differentially suppressed in tolerance identified calcium signaling, ion channels and excitatory neurotransmitter receptors, and the synapse as over-represented among pathways, functions and compartments. Finally, 12 days continuous EEG recordings determined mice with induced tolerance had fewer spontaneous electrographic seizures compared to the injury group. Our data suggest the transcriptional phenotype of neuroprotection in tolerance may be dictated by the biology of the preconditioning stressor, functions by transcriptional reduction of vulnerability to excitotoxicity, and has anti-epileptogenic effects.


Assuntos
Cálcio/metabolismo , Hipocampo/fisiopatologia , Neurônios/fisiologia , Estado Epiléptico/fisiopatologia , Análise de Variância , Animais , Morte Celular/genética , Cicloeximida/farmacologia , Eletroencefalografia , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Hipocampo/lesões , Hipocampo/patologia , Canais Iônicos/genética , Ácido Caínico/farmacologia , Potenciação de Longa Duração , Camundongos , Análise em Microsséries , Análise de Sequência com Séries de Oligonucleotídeos , Receptores de Neurotransmissores/genética , Estado Epiléptico/genética , Estado Epiléptico/patologia
3.
Nucleic Acids Res ; 33(19): 6287-95, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16269821

RESUMO

The Bacillus subtilis LexA protein represses the SOS response to DNA damage by binding as a dimer to the consensus operator sequence 5'-CGAACN(4)GTTCG-3'. To characterize the requirements for LexA binding to SOS operators, we determined the operator bases needed for site-specific binding as well as the LexA amino acids required for operator recognition. Using mobility shift assays to determine equilibrium constants for B.subtilis LexA binding to recA operator mutants, we found that several single base substitutions within the 14 bp recA operator sequence destabilized binding enough to abolish site-specific binding. Our results show that the AT base pairs at the third and fourth positions from the 5' end of a 7 bp half-site are essential and that the preferred binding site for a LexA dimer is 5'-CGAACATATGTTCG-3'. Binding studies with LexA mutants, in which the solvent accessible amino acid residues in the putative DNA binding domain were mutated, indicate that Arg-49 and His-46 are essential for binding and that Lys-53 and Ala-48 are also involved in operator recognition. Guided by our mutational analyses as well as hydroxyl radical footprinting studies of the dinC and recA operators we docked a computer model of B.subtilis LexA on the preferred operator sequence in silico. Our model suggests that binding by a LexA dimer involves bending of the DNA helix within the internal 4 bp of the operator.


Assuntos
Bacillus subtilis/genética , Proteínas de Bactérias/metabolismo , Regiões Operadoras Genéticas , Proteínas Repressoras/metabolismo , Resposta SOS em Genética , Serina Endopeptidases/metabolismo , Proteínas de Bactérias/química , Proteínas de Bactérias/genética , Sítios de Ligação , Análise Mutacional de DNA , DNA Bacteriano/química , Modelos Moleculares , Mutação , Ligação Proteica , Estrutura Terciária de Proteína , Recombinases Rec A/genética , Proteínas Repressoras/química , Proteínas Repressoras/genética , Serina Endopeptidases/química , Serina Endopeptidases/genética
5.
Blood ; 104(13): 4287-93, 2004 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-15319290

RESUMO

Transferrin receptor 2 (TfR2) is a type 2 transmembrane protein expressed in hepatocytes that binds iron-bound transferrin (Tf). Mutations in TfR2 cause one form of hereditary hemochromatosis, a disease in which excessive absorption of dietary iron can lead to liver cirrhosis, diabetes, arthritis, and heart failure. The function of TfR2 in iron homeostasis is unknown. We have studied the regulation of TfR2 in HepG2 cells. Western blot analysis shows that TfR2 increases in a time- and dose-dependent manner after diferric Tf is added to the culture medium. In cells exposed to diferric Tf, the amount of TfR2 returns to control levels within 8 hours after the removal of diferric Tf from the medium. However, TfR2 does not increase when non-Tf-bound iron (FeNTA) or apo Tf is added to the medium. The response to diferric Tf appears to be hepatocyte specific. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis shows that TfR2 mRNA levels do not change in cells exposed to diferric Tf. Rather, the increase in TfR2 is attributed to an increase in the half-life of TfR2 protein in cells exposed to diferric Tf. Our results support a role for TfR2 in monitoring iron levels by sensing changes in the concentration of diferric Tf.


Assuntos
Receptores da Transferrina/química , Transferrina/farmacologia , Carcinoma Hepatocelular , Linhagem Celular Tumoral , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Células K562 , Cinética , Neoplasias Hepáticas , RNA Mensageiro/genética , Receptores da Transferrina/efeitos dos fármacos , Receptores da Transferrina/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA